【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Cancer-Treating Drugs
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Cancer Treatments
2.1 The Physiology of Cancer – Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer – Trends in the World
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival – Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World – More Must Be Done
2.3 Treating Tumours – How Can We Fight Back?
2.3.1 Chemotherapy – The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy – A Magic Bullet?
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents
3. The World Anti-Cancer Drug Market, 2014-2024
3.1 Global Anti-Cancer Drugs Market Forecast, 2014-2024
3.2 The Domination of Immunotherapies in 2013
3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2014-2024 – The Fastest Growing Segment
3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2014-2024
3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2014-2024 – A Move towards Personalisation
3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2014-2024
4. Leading National Markets, 2014-2024
4.1 Anti-Cancer Drugs – Leading Markets, 2013
4.2 The US Anti-Cancer Drugs Market, 2014-2024 – Continued Leadership or Terminal Decline?
4.2.1 The US Anti-Cancer Drugs Market, 2013
4.2.2 The US Anti-Cancer Drugs Market Forecast – A Matured Approach
4.2.3 The Regulatory Effect on the US Market
4.3 The Japanese Anti-Cancer Drug Market, 2014-2024 – Still Steady?
4.4 The EU5 Anti-Cancer Drugs Market, 2014-2024 – Rivalling the US in Importance
4.5 The BRIC Countries Anti-Cancer Drugs Market, 2014-2024 – Awakening Sleeping Giants?
4.5.1 The Brazilian Anti-Cancer Drugs Market, 2014-2024 – Expansion of the Middle Class
4.5.2 The Russian Anti-Cancer Drugs Market, 2014-2024 – Rising Cancer Rates Stimulate Revenue Increases
4.5.3 The Indian Anti-Cancer Drugs Market, 2014-2024 – Lucrative Opportunity for Growth
4.5.4 The Chinese Anti-Cancer Drugs Market, 2014-2024 – Can it Fulfil its Potential?
5. The Top 25 Anti-Cancer Drugs, 2014-2024
5.1 Avastin (Roche) – The World Market Leader
5.1.1 Avastin Revenue, 2010-2013 – Mixed Growth
5.1.2 Avastin Revenue Forecast – Still No.1?
5.2 Herceptin (Roche) – The Looming Impact of Patent Expiry
5.2.1 Herceptin Revenue, 2010-2013 – Still Rising
5.2.2 Herceptin Revenue Forecast – Generic Erosion
5.3 Rituxan/MabThera (Roche) – Slowing Growth
5.3.1 Rituxan Revenue, 2010-2013 – Still Strong
5.3.2 Rituxan Revenue Forecast – Heading for a Decline
5.4 Gleevec/Glivec (Novartis) – The Maturation of a Blockbuster
5.4.1 Glivec Revenue, 2010-2013
5.4.2 Glivec Revenue Forecast – What Does the Future Hold?
5.5 Revlimid (Celgene) – Celgene’s Top Revenue Generator
5.5.1 Revlimid Revenue, 2010-2013 – Still on the Rise
5.5.2 Revlimid Revenue Forecast – A Long Term Leader?
5.6 Alimta (Eli Lilly) – A Slow Decline?
5.6.1 Alimta Revenue, 2010-2013
5.6.2 Alimta Revenue Forecast– Revenue Erosion Looming
5.7 Velcade (J&J/Takeda) – Rising Steadily
5.7.1 Velcade Revenue, 2010-2013
5.7.2 Velcade Revenue Forecast – A Dependable Sales Generator
5.8 Erbitux (Bristol-Myers Squibb/ Merck KGaA) – Facing Tough Competition
5.8.1 Erbitux Revenue, 2010-2013
5.8.2 Erbitux Revenue Forecast – No More Growth?
5.9 Gardasil (Merck & Co) – The Rise of Preventions
5.9.1 Gardasil Revenue, 2010-2013
5.9.2 Gardasil Revenue Forecast – Still Growing Strong
5.10 Zytiga (Johnson & Johnson)
5.10.1 Zytiga Revenue, 2010-2013 – The Rise of a New Drug
5.10.2 Zytiga Revenue Forecast
5.11 Xeloda (Roche) – Patent Exclusivity and the Future
5.11.1 Xeloda Revenue, 2010-2013 – The Impact of Combination Therapies
5.11.2 Xeloda Revenue Forecast – A Slippery Slope
5.12 Tarceva (Roche)
5.12.1 Tarceva Revenue, 2010-2013 – No Clear Pattern
5.12.2 Tarceva Revenue Forecast
5.13 Afinitor (Novartis) – A Targeted Approach
5.13.1 Afinitor Revenue, 2010-2013 – Growing Fast
5.13.2 Afinitor Revenue Forecast
5.14 Sprycel (Bristol-Myers Squibb)
5.14.1 Sprycel Revenue, 2010-2013
5.14.2 Sprycel Revenue Forecast – How Long Will the Growth Last?
5.15 Tasigna (Novartis) – Moving on Up
5.15.1 Tasigna Revenue, 2010-2013
5.15.2 Tasigna Revenue Forecast – A Multi-Billion Dollar Product?
5.16 Sutent (Pfizer)
5.16.1 Sutent Revenue, 2010-2013
5.16.2 Sutent Revenue Forecast – No More Growth
5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
5.17.1 Nexavar Revenue, 2010-2013 – The Effect of Regional Sales
5.17.2 Nexavar Revenue Forecast – A Promising Start to the Decade
5.18 Xgeva (Amgen)
5.18.1 Xgeva Revenue, 2010-2013 – The Impact of New Indications
5.18.2 Xgeva Revenue Forecast
5.19 Zoladex (AstraZeneca)
5.19.1 Zoladex Revenue, 2010-2013
5.19.2 Zoladex Revenue Forecast
5.20 Yervoy (Bristol-Myers Squibb) – Starting to Make its Mark
5.20.1 Yervoy Revenue, 2011-2013
5.20.2 Yervoy Revenue Forecast – Will it Keep Growing?
5.21 Vidaza (Celgene) – What Growth Potential?
5.21.1 Vidaza Revenue, 2010-2013
5.21.2 Vidaza Revenue Forecast – Generic Impact
5.22 Treanda (Teva Pharmaceuticals)
5.22.1 Treanda Revenue, 2010-2013
5.22.2 Treanda Revenue Forecast – Stalled Growth?
5.23 Temodar/Temodal (Merck & Co.) – Falling off the Cliff?
5.23.1 Temodar/Temodal Revenue, 2010-2013
5.23.2 Temodar/Temodal Revenue Forecast
5.24 Faslodex (AstraZeneca) – The Counterpart to Zoladex
5.24.1 Faslodex Revenue, 2010-2013
5.24.2 Faslodex Revenue Forecast
5.25 Abraxane (Celgene) – Beginning the Climb
5.25.1 Abraxane Revenue, 2012-2013
5.25.2 Abraxane Revenue Forecast
6. Drugs Approved in 2013-2014: Potential Future Blockbusters
6.1 Approved Treatments in 2014
6.1.1 Beleodaq (Topotarget/Spectrum Pharmaceuticals)
6.1.1.1 Market Potential
6.1.2 Zykadia (Novartis) – The Rise of Kinase Inhibitors
6.1.2.1 Market Potential
6.1.3 Cyramza (Eli Lilly) – A Breakthrough for Gastric Cancer?
6.1.3.1 Market Potential
6.2 Approved Treatments in 2013
6.2.1 Imbruvica (Pharmacyclics)
6.2.1.1 Market Potential
6.2.2 Gazyva (Roche) – The First Breakthrough Therapy
6.2.2.1 Market Potential
6.2.3 Gilotrif (Boehringer Ingelheim)
6.2.3.1 Market Potential
6.2.4 Mekinist (GSK) – A First-in-Class Treatment for Melanoma
6.2.4.1 Market Potential
6.2.5 Tafinlar (GSK) – A Partner for Mekinist
6.2.5.1 Market Potential
6.2.6 Kadycla (Roche) – A Future Star
6.2.6.1 Market Potential – A Replacement for Herceptin?
6.2.7 Pomalyst (Celgene)
6.2.7.1 Market Potential
6.3 Drugs Approved in 2012 – How They’re Doing Now
6.3.1 Afinitor (Novartis) – Already a Blockbuster
6.3.1.1 Market Potential
6.3.2 Bosulif (Pfizer) – How Will it Perform?
6.3.2.1 Market Potential
6.3.3 Cometriq (Exelixis)
6.3.3.1 Market Potential
6.3.4 Erivedge (Roche) – Will It Become a Blockbuster?
6.3.4.1 Market Potential
6.3.5 Iclusig (Ariad)
6.3.5.1 Market Potential – Wider Uses?
6.3.6 Inlyta (Pfizer) – A Good Second-Line Option?
6.3.6.1 Market Potential
6.3.7 Kyprolis (Amgen)
6.3.7.1 Market Potential
6.3.8 Marqibo (Talon) – Will Its Revenue Grow?
6.3.8.1 Market Potential
6.3.9 Perjeta (Roche) – Joining the HER2 Family
6.3.9.1 Market Potential
6.3.10 Stivarga (Bayer)
6.3.10.1 Market Potential
6.3.11 Synribo (Teva)
6.3.11.1 Market Potential
6.3.12 Votrient (GSK)
6.3.12.1 Market Potential
6.3.13 Xtandi (Medivation) – Quickly Becoming a Popular Choice
6.3.13.1 Market Potential
6.3.14 Zaltrap (Sanofi)
6.3.14.1 Market Potential
7. Leading Companies for Cancer Treatments, 2014
7.1 Anti-Cancer Drug Market Dominated by Seven Companies
7.2 Roche – Leader of the Pack
7.2.1 Oncology Pipeline – Investment in the Future
7.2.2 Roche’s Future Direction in Cancer Treatment
7.3 Novartis – Closing the Gap on Roche
7.3.1 Oncology R&D Pipeline – What’s the Potential?
7.3.2 Future Directions for Novartis
7.4 Celgene – Pressing Need to Diversify?
7.4.1Celgene’s Oncology Pipeline – Safeguarding the Future
7.4.2 Future Directions for Celgene
7.5 Eli Lilly – Reliant on Alimta
7.5.1 Oncology R&D Pipeline – What Potential Exists?
7.5.2 The Future Direction of Eli Lilly
7.6 AstraZeneca – Climbing up the Ladder
7.6.1 Oncology Pipeline – Showing Promise
7.6.2 The Future Direction of AstraZeneca
7.7 Bristol-Myers Squibb
7.7.1 Oncology R&D Pipeline – What Potential Exists?
7.7.2 Future Direction of BMS
7.8 Merck & Co. – Prominent in Vaccines
7.8.1 Oncology Pipeline – Greater Focus on Cancer
7.8.2 The Future Direction of Merck
8. R&D Pipelines for Cancer Treatment
8.1 Breast Cancer Drugs Under Development
8.1.1 Neratinib (Puma Pharmaceuticals)
8.1.2 Palbociclib (Pfizer)
8.1.3 Veliparib (Abbvie)
8.1.4 NeuVax (Galena Biopharma)
8.1.5 Entinostat (Syndax)
8.2 Prostate Cancer Drugs Under Development
8.2.1 OMD-201 (Orion)
8.2.2 Tasquinimod (Active Biotech)
8.2.3 EMD-525797 (EMD Serono)
8.2.4 PROSTVAC (Bavarian Nordic)
8.3 Lung Cancer Drugs Under Development
8.3.1 Tecemotide (Merck Serono)
8.3.2 RG7446 (Roche)
8.3.3 Nivolumab (Bristol-Myers Squibb)
8.3.4 MEDI4736 (AstraZeneca)
8.3.5 TG4010 (Transgene)
8.4 Colorectal Cancer Drugs Under Development
8.4.1 Imprime PGG (Biothera)
8.4.2 Xilonix (Xbiotech)
8.4.3 TAS-102 (Taiho Pharmaceuticals)
8.4.4 HA-Irinotecan (Alchemia)
8.4.5 Aptocine (Light Sciences Oncology)
8.5 Cervical Cancer Drugs Under Development
8.5.1 ADXS-HPV (Advaxis)
8.5.2 V503 (Merck & Co.)
8.5.3 VGX-3100 (Inovio Pharmaceuticals)
8.6 Stomach Cancer Drugs Under Development
8.6.1 Rilotumumab (Amgen)
8.6.2 Onartuzumab (Roche)
8.6.3 Apatinib (Jiangsu Hengrui Medicine)
8.7 Liver Cancer Drugs Under Development
8.7.1 Tivantinib (ArQule)
8.7.2 Lenvatinib (Eisai Co.)
8.7.3 Pexa-Vec9 (Jennerex Biotherapeutics)
8.7.4 Brivanib (Bristol-Myers Squibb)
8.7.5 Muparfostat (Progen Pharmaceuticals)
8.8 Ovarian Cancer Drugs Under Development
8.8.1 Farletuzumab (Eisai)
8.8.2 Niraparib (TESARO)
8.8.3 Trebananib (Amgen)
8.8.4 SG2000 (Spirogen)
8.9 Bladder Cancer Drugs Under Development
8.9.1 Vesimune (Telormedix)
8.9.2 HS-410 (Heat Biologics)
8.9.3 EOquin (Allergan)
8.10 Non-Hodgkin’s Lymphoma Drugs Under Development
8.10.1 Idelalisib (Gilead)
8.10.2 IPI-145 (Infinity Pharmaceuticals)
8.10.3 ABT-199 (AbbVie)
8.10.4 GS-9973 (Gilead)
8.11 Leukaemia Drugs Under Development
8.11.1 Dinaciclib (Merck)
8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
8.11.3 Vosaroxin (Sunesis)
8.12 Kidney Cancer Drugs Under Development
8.12.1 IMA901 (Immatics)
8.12.2 ASG-003 (Argos Therapeutics)
8.12.3 Nilovumab (Bristol-Myers Squibb)
8.12.4 TRC105 (Tracon Pharmaceuticals)
8.13 Pancreatic Cancer Drugs Under Development
8.13.1 Algenpantucel-L (NewLink Genetics)
8.13.2 MM-398 (Merrimack)
8.13.3 MK-0752 (Merck & Co.)
9. Qualitative Analysis of the Anti-Cancer Drug Market 2014-2024
9.1 SWOT Analysis of the Anti-Cancer Drugs Market
9.1.1 Strengths of the Market
9.1.1.1 The Rising Incidence of Cancer
9.1.1.2 Ample Treatment Options Available
9.1.2 Weaknesses
9.1.2.1 The Challenges of Drug Development
9.1.2.2 The Complex Nature of Cancer
9.1.3 Opportunities in the Anti-Cancer Drugs Market
9.1.3.1 The Advancement of Research
9.1.3.2 A Shift Towards Personalisation
9.1.4 Threats Facing the Anti-Cancer Drugs Market
9.1.4.1 The Threat of Regulation
9.2 STEP Analysis of the Anti-Cancer Drugs Market
9.2.1 Social Factors: The Cost of Living Longer
9.2.2 Technological Developments: Making the Market Move Forward
9.2.3 Economic Pressure: Treatment’s Hefty Price Tag
9.2.4 Political Issues: Governmental Involvement in Treatment
10. Research Interviews
10.1 Interview with Mr Thomas Felzmann, CEO, Activartis Biotech GmbH, Vienna, Austria
10.1.1 Activartis Biotech and AV0113
10.2 Interview with Professor Philip Rudland, Chair of Biochemistry at the University of Liverpool
10.2.1 Identifying Markers in Cancer Cells
10.2.2 The Importance of Protein Expression
10.2.3. The Advancement of Diagnostics
10.2.4 The Future of the Anti-Cancer Drug Market
10.3 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University
10.3.1 On His Research Interests and their Utility in Anti-Cancer Drug Development
10.3.2 On the Evaluation of New Targets for Anti-Cancer Drugs
10.3.3 On Drug Resistance and Targeted Therapies
10.3.4 On the Future of Traditional Chemotherapy
10.3.5 On Future Developments in the Anti-Cancer Field
10.4 Interview with Dr Neil Butt, Director, Antitope Ltd.
10.4.1 On Immunogenicity in Therapeutic Proteins
10.4.2 On Antitope’s Technologies to Assess and Reduce Immunogenicity
10.4.3 On an Alternative Way of Reducing Immunogenicity
10.4.4 On Biosimilars
10.4.5 On Future Developments in that Field
11. Conclusions of the Study
11.1 The Top 25 Drugs in the Cancer Treatment Market
11.2 Immunotherapies – The Future of the Market
11.3 Patent Expiries and the Impact of Biosimilars
11.4 The US – Still the Largest National Market
11.5 China and Brazil Will Lead the Emerging Markets
11.6 Treatment – It’s Personal
11.7 The Anti-Cancer Drug Pipeline Remains Strong
11.8 Concluding Remarks
【レポート販売概要】
■ タイトル：世界の抗がん剤市場：治療法、研究開発動向及び市場予測■ 英文：ANTI-CANCER DRUGS INDUSTRY AND MARKET: THERAPIES, R&D AND FORECASTS 2014-2024
■ 発行日：2014年8月
■ 調査会社：visiongain
■ 商品コード：VISG409045
■ 調査対象地域：グローバル
- 世界のクリーン石炭設備市場：Analyzing the Global Market for Clean Coal EquipmentCoal is expected to continue to be a dominant fuel in power generation due to its low cost and abundance. Nearly ten billion tons of coal was produced globally in 2012, and over 40% of global electricity was coal powered. On a levelized cost of production basis, the global market value of coal-fired electricity exceeded $400 billion. Nonetheless, conventional coal power generation is a leading con …
- Thromboembolism：グローバル臨床試験レビューH1, 2013Thromboembolism Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Thromboembolism Global Clinical Trials Review, H1, 2013" provides data on the Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thromboembolism. It includes an overview of the trial numbers and their recruitment status as …
- 高温耐熱性接着剤の世界市場：エポキシ接着剤、シリコン接着剤、アクリル接着剤、ポリウレタン接着剤The high temperature adhesives market size in terms of value is projected to grow at a CAGR of 4.6% between 2014 and 2019 to reach $4.02 billion by 2019. Asia-Pacific held the largest share in high temperature adhesives market in 2013. Major growth in the Asia-Pacific region is expected from the growing automotive and electronics application. The high temperature adhesives market in Asia-Pacific r …
- 世界の分数馬力モーター（小形電動機）市場About Fractional Horsepower Motors An electric motor is a device that converts electric energy into mechanical motion. There are two types of electric motors based on their power classification: fractional horsepower motors and integral horsepower motors. Fractional horsepower motors are those that have an output power of less than 1 HP. These motors are mainly used in Home Appliance, HVAC, Water …
- Vectibix：大腸癌治療薬市場分析Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on …
- 世界のガスエンジン市場：燃料種類別（天然ガス、特殊ガス）、用途別（発電、コージェネレーション、機械駆動）、エンドユーザー別（ユーティリティ、製造、石油およびガス）、出力別（0.5–1MW、1–2MW、2–5MW、5–10 MW、10–20MW）、地域別“The gas engines market is projected to grow at a CAGR of 5.7% from 2019 to 2024.” The global gas engines market size is projected to reach USD 5.3 billion by 2024, from an estimated value of USD 4.0 billion in 2019, growing at a CAGR of 5.7% during the forecast period. Gas engines are used mainly for power generation applications and CHP applications. The growth of the gas engines industry can be …
- 石油・ガス貯蔵サービスの世界市場2016-2020：貯蔵サービス、付帯サービスAbout Oil and Gas Storage Service Storage tank services are responsible for over 70% of the revenue in the market and include containers that hold liquids, compressed gases, or mediums used for short- or long-term storage. Typically, these tanks operate under no or very little pressure and can be spherical or cylindrical in shape. Based upon location and requirement, storage tanks come in varietie …
- 転移性腎細胞癌：グローバル臨床試験レビュー（2014年上半期）Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Renal Cell Carcinoma. It includes …
- 初代細胞の世界市場予測（～2023年）：造血、血液、皮膚、消化器官、肝細胞、腎細胞、骨格・筋肉The global primary cells market is expected to reach USD 1,107.3 million by 2023 from USD 736.4 million in 2018, at a CAGR of 8.5%. Growth in the primary cells market is mainly driven by factors such as increasing cancer research; the advantages of primary human cells over cell lines; the increasing demand for monoclonal antibodies; rapid growth in the biotechnology and biopharmaceutical industrie …
- 世界のミクロスフェア（Microsphere）市場Rising demand for efficiency and better materials with superior structural properties will drive the global microspheres market to $5.2 billion by 2018. U.S. leads the world in terms of usage of advanced materials to increase the efficiency and reliability of operations which makes it the biggest market for microspheres. The market here is expected to experience highest revenue growth during the n …
- 世界のウェーハ洗浄装置市場：装置種類別（枚葉式スプレーシステム、バッチ式スプレー洗浄システム、スクラバー）、用途別、技術別、動作モード別、ウェーハサイズ別、地域別“The wafer cleaning equipment market projected to grow at a CAGR of 10.3% during 2020–2025.” The wafer cleaning equipment market size is expected to grow from USD 7.4 billion in 2020 to USD 12.1 billion by 2025; it is projected to grow at a CAGR of 10.3% during the forecast period. Rise in the conventional application of MEMS and expansion in the number of cleaning steps in the wafer manufacturing …
- オーストラリアの食品安全検査市場The Australian food safety testing market is gaining growing level of importance in the country owing to continual increase in number of food-born disease outbreaks, increasingly stringent regulations on food safety, growing level of trade between Australia and other countries, sustained number of food recalls, among others. Rapid technologies dominate the Australian food safety testing market owi …
- 中国の電力ケーブル市場2016-2020About Power Cable A power cable is primarily an assembly of one or more electrical conductors, usually held together by an overall sheath. Power cables are used for transmission and, in some cases, distribution of large quantities of electrical power. Power cables have three basic components, namely, conductor, insulation, and protective covering or sheath. Other than the three basic components, t …
- Rock Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013Rock Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Rock Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
- 世界の地域冷房サービス市場：商業用、住宅用、工業用冷房The district cooling market can be segmented into four major regions, which are the Americas, the Middle East & Africa (MEA), Europe, and Asia-Pacific. These regions are further segmented into major countries based on the usage of district cooling. The report covers country level study for twenty countries out of which, some are the U.S., UAE, Saudi Arabia, Qatar, Sweden, France, Japan, Korea, Sin …
